{"id":43810,"date":"2026-05-03T02:25:15","date_gmt":"2026-05-03T07:25:15","guid":{"rendered":"https:\/\/www.heart-valve-surgery.com\/heart-surgery-blog\/?p=43810"},"modified":"2026-05-03T17:07:03","modified_gmt":"2026-05-03T22:07:03","slug":"commence-clinical-trial-results","status":"publish","type":"post","link":"https:\/\/www.heart-valve-surgery.com\/heart-surgery-blog\/2026\/05\/03\/commence-clinical-trial-results\/","title":{"rendered":"Clinical Trial Update: The COMMENCE Study 10-Year Results Released at AATS"},"content":{"rendered":"

I just heard from Dr. Lars Svensson<\/a>, Chief of the Heart, Vascular and Thoracic Institute at the Cleveland Clinic, that the updated results of the COMMENCE trial just were shared at the American Association for Thoracic Surgery Conference<\/a> that is happening right now in Chicago, Illinois.<\/p>\n

 <\/p>\n

\"Edwards<\/p>\n

INSPIRIS RESILIA Tissue Valve Studied in COMMENCE Trial<\/p>\n

 <\/p>\n

<\/p>\n

 
\nDr. Svensson shared, “I just had the privilege of presenting the COMMENCE Trial results at AATS. The 10-year data is encouraging, showing low rates of structural valve deterioration and reoperation, even in younger patients who typically face higher risks. This tissue technology could reshape how we think about biological valve durability. Long-term evidence matters.”<\/p>\n

 <\/p>\n

\n

Presented the COMMENCE Trial at #AATS2026<\/a> – the 10 yr data is encouraging, showing low rates of structural valve deterioration & reoperation, even in younger pts who typically face higher risks.<\/p>\n

This tissue technology could reshape how we think about biological valve durability. pic.twitter.com\/IBBuZrl2Dw<\/a><\/p>\n

\u2014 Lars Svensson (@LarsSvenssonMD) May 2, 2026<\/a><\/p><\/blockquote>\n